Then the market hit an inflection point: GLP-1 stopped being metabolic medicine and became a category-defining obesity engine, with downstream effects across payer policy, manufacturing capacity, and portfolio strategy
Semaglutide can cause heart palpitations and a mildly increased pulse, typically raising resting heart rate by 2 to 4 beats per minute
It inhibits GSK3-beta, a component of the destruction complex that breaks down beta-catenin
Monjaro vs Ozempic at a glance: approvals, dosing, and use Approvals 1
Global health: Finally, the sheer scale raises questions of global health allocation
Shifting from rats to human clinical trials, Moussawi latest research focuses on the GLP-1 brenipatide, which is thought to target craving and drug use